ATE507836T1 - 2-o, 3-o desulfatiertes heparin zur behandlung von heparininduzierter thrombozytopenie (hit) - Google Patents
2-o, 3-o desulfatiertes heparin zur behandlung von heparininduzierter thrombozytopenie (hit)Info
- Publication number
- ATE507836T1 ATE507836T1 AT05824840T AT05824840T ATE507836T1 AT E507836 T1 ATE507836 T1 AT E507836T1 AT 05824840 T AT05824840 T AT 05824840T AT 05824840 T AT05824840 T AT 05824840T AT E507836 T1 ATE507836 T1 AT E507836T1
- Authority
- AT
- Austria
- Prior art keywords
- heparin
- desulfated
- medicament
- desulfated heparin
- hit
- Prior art date
Links
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical class OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 title abstract 4
- 206010062506 Heparin-induced thrombocytopenia Diseases 0.000 title 2
- 239000003814 drug Substances 0.000 abstract 3
- 238000000034 method Methods 0.000 abstract 2
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 abstract 1
- 208000007536 Thrombosis Diseases 0.000 abstract 1
- 238000012387 aerosolization Methods 0.000 abstract 1
- 239000007975 buffered saline Substances 0.000 abstract 1
- 239000012153 distilled water Substances 0.000 abstract 1
- 150000002772 monosaccharides Chemical class 0.000 abstract 1
- 230000010118 platelet activation Effects 0.000 abstract 1
- QAOWNCQODCNURD-UHFFFAOYSA-L sulfate group Chemical group S(=O)(=O)([O-])[O-] QAOWNCQODCNURD-UHFFFAOYSA-L 0.000 abstract 1
- 230000019635 sulfation Effects 0.000 abstract 1
- 238000005670 sulfation reaction Methods 0.000 abstract 1
- 230000002194 synthesizing effect Effects 0.000 abstract 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/726—Glycosaminoglycans, i.e. mucopolysaccharides
- A61K31/727—Heparin; Heparan
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/715—Polysaccharides, i.e. having more than five saccharide radicals attached to each other by glycosidic linkages; Derivatives thereof, e.g. ethers, esters
- A61K31/737—Sulfated polysaccharides, e.g. chondroitin sulfate, dermatan sulfate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08B—POLYSACCHARIDES; DERIVATIVES THEREOF
- C08B37/00—Preparation of polysaccharides not provided for in groups C08B1/00 - C08B35/00; Derivatives thereof
- C08B37/006—Heteroglycans, i.e. polysaccharides having more than one sugar residue in the main chain in either alternating or less regular sequence; Gellans; Succinoglycans; Arabinogalactans; Tragacanth or gum tragacanth or traganth from Astragalus; Gum Karaya from Sterculia urens; Gum Ghatti from Anogeissus latifolia; Derivatives thereof
- C08B37/0063—Glycosaminoglycans or mucopolysaccharides, e.g. keratan sulfate; Derivatives thereof, e.g. fucoidan
- C08B37/0075—Heparin; Heparan sulfate; Derivatives thereof, e.g. heparosan; Purification or extraction methods thereof
-
- C—CHEMISTRY; METALLURGY
- C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
- C08L—COMPOSITIONS OF MACROMOLECULAR COMPOUNDS
- C08L5/00—Compositions of polysaccharides or of their derivatives not provided for in groups C08L1/00 or C08L3/00
- C08L5/10—Heparin; Derivatives thereof
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Molecular Biology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Dermatology (AREA)
- Polymers & Plastics (AREA)
- Epidemiology (AREA)
- Hematology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Diabetes (AREA)
- Biochemistry (AREA)
- Materials Engineering (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Polysaccharides And Polysaccharide Derivatives (AREA)
- Medicinal Preparation (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US10/974,566 US7468358B2 (en) | 2004-06-16 | 2004-10-27 | Method and medicament for sulfated polysaccharide treatment of heparin-induced thrombocytopenia (HIT) syndrome |
| PCT/US2005/039011 WO2006047755A2 (en) | 2004-10-27 | 2005-10-26 | Method and medicament for sulfated polysaccharide treatment of heparin-induced thrombocytopenia (hit) syndrome |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| ATE507836T1 true ATE507836T1 (de) | 2011-05-15 |
Family
ID=36228513
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| AT05824840T ATE507836T1 (de) | 2004-10-27 | 2005-10-26 | 2-o, 3-o desulfatiertes heparin zur behandlung von heparininduzierter thrombozytopenie (hit) |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US7468358B2 (enExample) |
| EP (1) | EP1807095B1 (enExample) |
| JP (1) | JP2008518090A (enExample) |
| AT (1) | ATE507836T1 (enExample) |
| AU (1) | AU2005299568A1 (enExample) |
| CA (1) | CA2585640C (enExample) |
| DE (1) | DE602005027883D1 (enExample) |
| ES (1) | ES2366342T3 (enExample) |
| WO (1) | WO2006047755A2 (enExample) |
Families Citing this family (18)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050261241A1 (en) * | 2004-05-19 | 2005-11-24 | Celsus Biopharmaceuticals, Inc. | Use of dermatan sulfates and/or desulfated heparins to treat or prevent heparinoid-induced autoimmune responses |
| WO2008106584A1 (en) * | 2007-02-28 | 2008-09-04 | Paringenix, Inc. | O-desulfated heparins treating acute exacerbations of chronic obstructive pulmonary disease |
| WO2009015183A1 (en) * | 2007-07-23 | 2009-01-29 | University Of Utah Research Foundation | Method for blocking ligation of the receptor for advanced glycation end-products (rage) |
| WO2009117677A2 (en) * | 2008-03-21 | 2009-09-24 | University Of Utah Research Foundation | Methods for controlling intracellular calcium levels associated with an ischemic event |
| WO2011014793A2 (en) | 2009-07-31 | 2011-02-03 | Reliable Biopharmaceutical Corporation | Process for preparing fondaparinux sodium and intermediates useful in the synthesis thereof |
| US8420790B2 (en) | 2009-10-30 | 2013-04-16 | Reliable Biopharmaceutical Corporation | Efficient and scalable process for the manufacture of Fondaparinux sodium |
| DK3144325T3 (da) * | 2010-09-14 | 2021-01-25 | Univ Miyazaki | Heparin med høj renhed og fremstillingsfremgangsmåde dertil |
| DK2646037T3 (en) * | 2010-12-01 | 2019-03-04 | Univ Australian National | use of polyanions to inhibit the cytotoxic activity of histones in the treatment of sepsis |
| WO2013016181A1 (en) * | 2011-07-22 | 2013-01-31 | Paringenix, Inc. | Compositions and methods for anti-coagulation |
| WO2013115817A1 (en) | 2012-02-02 | 2013-08-08 | Reliable Biopharmaceutical Corporation | An efficient and scalable process for the manufacture of fondaparinux sodium |
| BR112014028094B1 (pt) | 2012-05-09 | 2022-03-03 | Cantex Pharmaceuticals, Inc | Uso de um heparinoide interagindo com fator de plaqueta 4 |
| AU2016234916A1 (en) * | 2012-05-09 | 2016-11-17 | Cantex Pharmaceuticals, Inc. | Treatment of myelosuppression |
| US20170096549A1 (en) | 2014-03-17 | 2017-04-06 | Cantex Pharmaceuticals, Inc. | Multivalent cation formulations of partially desulfated heparins |
| EP3258941A4 (en) | 2015-02-17 | 2018-09-26 | Cantex Pharmaceuticals, Inc. | Treatment of cancers and hematopoietic stem cell disorders privileged by cxcl12-cxcr4 interaction |
| CN107430137B (zh) | 2015-03-03 | 2020-11-20 | 美国控股实验室公司 | 用于测量样品中的血清素的方法和系统 |
| CA3102284A1 (en) * | 2018-06-03 | 2019-12-12 | Glycomira Therapeutics, Inc. | Methods for preventing a serious health consequence and/or tissue damage after exposure to ionizing radiation and/or chemotherapy |
| WO2022015794A1 (en) | 2020-07-14 | 2022-01-20 | Optimvia, Llc | Methods for synthesizing non-anticoagulant heparan sulfate |
| GB202006960D0 (en) * | 2020-05-12 | 2020-06-24 | Aplagon Oy | Therapeutic |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1164145B1 (en) * | 1992-07-24 | 2007-12-05 | Thomas P. Kennedy | Non-anticoagulant desulfated heparins as medicaments |
| US5668118A (en) * | 1992-07-24 | 1997-09-16 | Cavalier Pharmaceuticals | Method of synthesis of 2-O-desulfated Heparin and use thereof for inhibition of elastase and Cathepspin G |
| US5696100A (en) * | 1992-12-22 | 1997-12-09 | Glycomed Incorporated | Method for controlling O-desulfation of heparin and compositions produced thereby |
| US5990097A (en) * | 1996-07-29 | 1999-11-23 | Cavalier Pharmaceuticals | Methods of treating asthma with o-desulfated heparin |
| EP1128842B1 (en) * | 1998-11-13 | 2006-03-15 | Eli Lilly And Company | Use of human protein c for the manufacture of a medicament for treating heparin-induced thrombocytopenia |
| WO2001019376A2 (en) | 1999-09-13 | 2001-03-22 | Charlotte-Mecklenburg Hospital Authority D/B/A Carolinas Medical Center | METHOD OF INHIBITING NF-λB WITH HEPARIN, FOR TREATING CARDIOVASCULAR DISEASES AND INFLAMMATIONS |
| US6489311B1 (en) | 2000-05-02 | 2002-12-03 | Charlotte-Mecklenburg Hospital Authoirty | Method for the prevention of apoptosis |
| WO2004050673A2 (en) | 2002-11-27 | 2004-06-17 | Massachusetts Institute Of Technology | Methods for synthesizing polysaccharides |
| US20050261241A1 (en) * | 2004-05-19 | 2005-11-24 | Celsus Biopharmaceuticals, Inc. | Use of dermatan sulfates and/or desulfated heparins to treat or prevent heparinoid-induced autoimmune responses |
| US20050282775A1 (en) * | 2004-06-16 | 2005-12-22 | Paringenix, Inc. | Method and medicament for sulfated polysaccharide treatment of inflammation without inducing platelet activation and heparin-induced thrombocytopenia syndrome |
-
2004
- 2004-10-27 US US10/974,566 patent/US7468358B2/en not_active Expired - Lifetime
-
2005
- 2005-10-26 JP JP2007539188A patent/JP2008518090A/ja active Pending
- 2005-10-26 AU AU2005299568A patent/AU2005299568A1/en not_active Abandoned
- 2005-10-26 AT AT05824840T patent/ATE507836T1/de not_active IP Right Cessation
- 2005-10-26 DE DE602005027883T patent/DE602005027883D1/de not_active Expired - Lifetime
- 2005-10-26 EP EP05824840A patent/EP1807095B1/en not_active Expired - Lifetime
- 2005-10-26 ES ES05824840T patent/ES2366342T3/es not_active Expired - Lifetime
- 2005-10-26 WO PCT/US2005/039011 patent/WO2006047755A2/en not_active Ceased
- 2005-10-26 CA CA2585640A patent/CA2585640C/en not_active Expired - Lifetime
Also Published As
| Publication number | Publication date |
|---|---|
| CA2585640A1 (en) | 2006-05-04 |
| CA2585640C (en) | 2012-01-10 |
| EP1807095B1 (en) | 2011-05-04 |
| US20070123489A1 (en) | 2007-05-31 |
| US7468358B2 (en) | 2008-12-23 |
| AU2005299568A1 (en) | 2006-05-04 |
| WO2006047755A2 (en) | 2006-05-04 |
| JP2008518090A (ja) | 2008-05-29 |
| EP1807095A2 (en) | 2007-07-18 |
| WO2006047755A3 (en) | 2007-02-01 |
| ES2366342T3 (es) | 2011-10-19 |
| EP1807095A4 (en) | 2008-08-27 |
| DE602005027883D1 (de) | 2011-06-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| DE602005027883D1 (de) | 2-o, 3-o desulfatiertes heparin zur behandlung von heparininduzierter thrombozytopenie (hit) | |
| Kidane et al. | Anticoagulant and antiplatelet agents: their clinical and device application (s) together with usages to engineer surfaces | |
| DE50310724D1 (de) | Herstellung von suspension hydrophober oxidpartikel | |
| DE69928219D1 (de) | Lipasehemmende polymere | |
| WO2005012364A3 (fr) | Matrice complexe a usage biomedical | |
| ATE478867T1 (de) | Substituierte quinazolinone verbindungen | |
| BR9608330A (pt) | Copolìmero em bloco heterotelequélico e um método para a produção do mesmo. | |
| BR0010380A (pt) | Método, composição farmacêutica, kit e uso de uma combinação para prevenção e tratamento de diversas disfunções tromboembólicas e métodos de tratamento de trombose em mamìferos | |
| DK0981381T3 (da) | Polyhydroxyalkanoater ti anvendelser in vivo | |
| UA100378C2 (uk) | Полімерна композиція, спосіб її виготовлення, виріб, спосіб його виготовлення та спосіб формування, застосування, спосіб підвищення швидкості текучості розплаву суміші та спосіб зменшення технологічного циклу формування виробу | |
| BR8304973A (pt) | Mistura de polimero compativel | |
| MXPA05006414A (es) | Poliazoles de alto peso molecular. | |
| MX2025002806A (es) | Combinaciones terapeuticas para los trastornos del movimiento | |
| JP2008518090A5 (enExample) | ||
| BRPI0416088A (pt) | composição, sistema, e método de tratar condições tais como calcificação vascular | |
| ATE359798T1 (de) | Verwendungvon dextransulfat zur behandlung von ibmir | |
| CY1105020T1 (el) | Υποκαταστατες διαζεπανες | |
| WO2004044223A3 (en) | Prodrugs of vancomycin with hydrolysis resistant polymer linkers | |
| EP1561760A3 (en) | Low molecular weight heparin salt with thriethanolamine | |
| BR112021010615A2 (pt) | Clazakizumab no tratamento de rejeição crônica de transplante de órgãos mediada por anticorpos | |
| EP1940439A4 (en) | REDUCTION OF POSTOPERATIVE ADHESION FORMATION WITH INTRAPERITONEAL GLUTAMINE | |
| IL165808A0 (en) | Low molecular weight k5-n,o-oversulfated polysaccharide process for the preparation thereof and pharmaceutical compositions containing the same | |
| CA2434393A1 (en) | Heparin with average molecular mass | |
| WO2001015654A3 (fr) | Polysaccharide antithrombotique de bas poids moleculaire | |
| WO2009137899A3 (en) | Sulfated galactans with antithrombotic activity, pharmaceutical composition, method for treating or prophylaxis of arterial or venous thrombosis, method of extraction and use thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| RER | Ceased as to paragraph 5 lit. 3 law introducing patent treaties |